US Patent

US11602536 — Topical treatment of vitiligo by a JAK inhibitor

Method of Use · Assigned to Incyte Corp · Expires 2041-05-05 · 15y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of using ruxolitinib or a pharmaceutically acceptable salt thereof to topically treat vitiligo.

USPTO Abstract

The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3550`	—	ruxolitinib-phosphate

Patent Metadata

Patent number: US11602536
Jurisdiction: US
Classification: Method of Use
Expires: 2041-05-05
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.